Pages Menu
FacebookTwitterPinterestRss
Categories Menu

Posted by on Jan 28, 2015 in Foundation NewsLine |

Update from Genzyme on Acid Sphingomyelinase Deficiency (ASMD) Development Efforts Adult Trial ~ January 28th, 2015

Dear NNPDF Families and Friends,
The NNPDF is pleased to provide you with the following update from Genzyme, a Sanofi Company, on NEWLY released information about the adult Phase 2 / 3 clinical trial of recombinant human acid sphingomyelinase (rhASM).
Visit the NNPDF Genzyme web page to view the full announcement: http://www.nnpdf.org/npresearch_11.html#Jan282015
Please be advised of the following details associated with the adult Phase 2 / 3 clinical trial #: NCT02004691:
  • The study is NOT yet open for patient recruitment
  • Inclusion / Exclusion criteria are provided in the post
  • Estimated enrollment of 35 adult patients
  • MUST be 18 years and older
  • The number of country clinical sites and locations has NOT yet been determined ~ but there will be clinic sites in multiple countries.